Lindstrom Eyes Improvements to Eye Drops

Richard Lindstrom, MD, led the OIS@ASRCS breakfast breakout session “Innovative Alternatives to Drops.” Hear his recap of the problem and the potential solutions that may someday help current and new medicines reach the areas of the eye that need them most. Video Highlights: 00:48 – If everyone used their eye drops they’d be quite safe…

Read More

What the Heck Happened at OIS@ASCRS? – OIS Podcasts Hit Some Highlights from Last Week’s Stellar Meeting in New Orleans

What the Heck Happened at OIS@ASCRS? OIS Podcasts Hit Some Highlights from Last Week’s Stellar Meeting in New Orleans - OIS Podcast

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 085″] The fifth OIS@ASCRS delivered highlights on diagnostics, glaucoma devices, and What The Future of ophthalmology might bring. OIS Podcasts will provide a quick review of the day for those who couldn’t make it (or simply had overstuffed their meeting calendar in New Orleans). Tom Salemi: Hi, Everyone, welcome back to…

Read More

Masters of The Universe

The day concluded with the Masters of the Universe panel where AcuFocus executive chairman Jim Mazzo led a discussion between Link and executives from Abbott Medical Optics, Alcon, Allergan, Bausch & Lomb, Carl Zeiss Meditec, and Johnson & Johnson Vision Care. Mazzo introduced the panel – and the notion of industry consolidation – with a…

Read More

The “Post-Game Wrap-Up” with OIS@ASCRS Co-Chairs

The “Post-Game Wrap-Up” with OIS@ASCRS Co-Chairs - OIS@ASCRS 2016

OIS co-chairs and VCs Emmett Cunningham, MD, Gil Kliman, MD, and Bill Link, PhD, sit down with OISTV to review the highlights of the May 5 OIS@ASCRS in New Orleans. Topics include the purpose for OIS, plans for future meetings, and advances in ophthalmology treatments. Video Timestamp: 00:52 – The benefit of the breakout sessions.…

Read More

Graybug Vision – Making Big Moves

Graybug Vision – Flush with Cash – Is Making Big Moves to Change Its Approach to Finding New Treatments for Wet AMD and Other Eye Disease - OIS Podcast

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 084″] Graybug interim CEO Jeff Cleland shares details on the company’s $44.5 million Series B. Cleland gives a report on investor appetite for ophthalmology companies. He also explains how the firm would use the capital to shift its approach from a drug delivery platform technology company to a drug maker. Ten…

Read More

Sun Ophthalmics Looks to Build a Brand-New Business in the US

Sun Ophthalmics Looks to Build a Brand-new Business in the US - OIS Podcast

Sun Pharma, the fifth largest pharma company in the US, targeted ophthalmology as one of the first planks in its new branded pharma business. Hear ophthalmology veteran Jerry St. Peter explain how Sun Ophthalmics hopes to build a new team in ophthalmology. Ten Top Topics in this OIS Podcast: What are the origins of Sun…

Read More

KOL Corner: Can Complement Inhibitors Treat Macular Degeneration?

OIS Podcast

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 080″] The complement system is a promising target for drugs being developed to treat macular degeneration. But success has been elusive. A leading KOL and two CEOs explain what the future of the field may be. Podcast Transcript Tom Salemi: Hi, everyone, welcome back to the OIS Podcast. This is your…

Read More

What’s New with Three Sustained-Release Drug Platforms

What’s New With Three Sustained-Release Drug Platforms - Eye on Innovation

Most ophthalmic drugs are delivered by topical application or direct injection into the vitreous, and many are limited by difficulties in sustaining therapeutic drug levels or by problems with patient adherence. As effective as topical drops are for delivering medication to the eye, they are wholly dependent on patient adherence. Even patients with potentially blinding…

Read More

Lewis Handicaps MIGS Market & Explains Glaucoma’s Emergence

Lewis Handicaps MIGS Market and Explains Glaucoma’s Emergence - OIS Podcast

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 077″] Glaucoma specialist Dr. Richard Lewis says glaucoma was once the “boring step sister” of the ophthalmology world. But now the chief medical officer of Aerie says the rise in devices and drugs has made glaucoma one of the coolest kids in ophthalmology’s school yard. 10 Top Topics in this OIS…

Read More

The OIS Lifetime Innovator Award goes to…

Roger Steinert, MD     For A Lifetime of Exceptional Contributions to Ophthalmic Innovation and Entrepreneurship Dr. Steinert’s advanced skill and excellent surgical results have earned him a reputation as an international consultant and leader in cataract surgery, refractive surgery and corneal transplants. He has conducted numerous, high-profile research studies and remains at the forefront…

Read More

VisionCare Battling Back Against Macular Degeneration

OIS Podcast - Eye on Innovation

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 076″] CEO Wolfgang Tolle joined VisionCare last year to move the company into the commercial stage. Now with long-term data and reimbursement in place, the firm is making a strong commercial push. Transcript Tom Salemi: Hello, OIS Podcast listeners, this is Tom Salemi, your host. Thanks for joining us today on…

Read More

KOL Corner: Alcon, Transcend & Glaucoma 360

OIS Podcast

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 074″] Glaucoma once might have been a boring or sleepy sub-specialty of ophthalmology, but recent technical advances and significant bets placed by large strategics including Alcon’s planned ac-quisition of Transcend has injected the sector with enthusiasm and energy. OIS Podcast, in our new KOL Corner features, talks with leading glaucoma specialists…

Read More